Last
Update:
April 28, 2018
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
Journal
Papers, Abstracts, and Commentaries
| |
Direct-acting antiviral drugs for chronic hepatitis C and risk of
major vascular events: a systematic review.
Tamborini Permunian E, Gervaso L,
et al
Intern Emerg Med. 2018 Apr
2
Abstract
Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis
C: When Is the Optimal Time to Treat?
Cervino L, Hynicka LM.
Ann
Pharmacother. 2018 Apr 1:
Abstract
Predicting Early Viral Control under Direct-Acting Antiviral Therapy for
Chronic Hepatitis C Virus Using Pretreatment Immunological Markers.
Hutchinson JA, Weigand K, Adenugba A, et al
Front Immunol. 2018 Feb
7;9:146.
Abstract
Viral eradication reduces both liver stiffness and steatosis in patients
with chronic hepatitis C virus infection who received direct-acting
anti-viral therapy.
Tada T, Kumada T, Toyoda H, Sone Y,
et al
Aliment Pharmacol Ther.
2018 Feb 9
Abstract
Abstract
Abstract
Efficacy of Generic Oral Directly Acting Agents in Patients with Hepatitis
C Virus Infection.
Gupta S, Rout G, Patel AH,
et al
J Viral Hepat.
2018 Jan 28.
Abstract
HCV-DAA therapy impacts on extracellular vesicles miRNAs
content and on their immunomodulating properties.
Santangelo L, Bordoni V, Montaldo C,
et al
Liver Int.
2018 Jan 22.
Abstract
Uptake of direct acting antiviral treatment for chronic hepatitis
C in Australia.
Hajarizadeh B, Grebely J, Matthews GV,
J Viral Hepat.
2017 Dec 23.
Abstract
HCV eradication by DAA improves glucose tolerance and reduces
post-load insulin resistance in nondiabetic patients with genotype 1.
Salomone F, Catania M, Montineri A,
Liver Int.
2017 Dec
19.
Abstract
HCV-positive lymphoma after sustained virological response with
direct-acting antiviral agents: The game is not over after HCV
eradication.
Rodríguez de Santiago E, Velázquez Kennedy K,
ínez A., et al
J Viral Hepat.
2017 Dec 14.
Abstract
HCV clearance by direct-acting antiviral treatments reverses insulin
resistance in chronic hepatitis C patients
Adinolfi LE, Nevola R, Guerrera B,
et al
J Gastroenterol Hepatol.
2017 Dec 11.
Abstract
Benefits of Direct-Acting Antivirals for Hepatitis C
Lok AS, Chung RT, Vargas HE,
et al
Ann Intern Med.
2017 Dec 5;167(11):812-813.
Abstract
The short-term incidence of hepatocellular carcinoma is not
increased after hepatitis C treatment with direct-acting antivirals: An
ERCHIVES study.
Li DK, Ren Y, Fierer DS, Rutledge S,
et al
Hepatology.
2017 Dec 2.
Abstract
State Medicaid hepatitis C treatment eligibility criteria and use of direct
acting antivirals.
Kapadia SN, Jeng PJ, Schackman BR, Bao Y.
Clin
Infect Dis. 2017 Dec 1.
Abstract
Changes in liver function and body composition by direct-acting antiviral
therapy for hepatitis C virus infection.
Sugimoto R, Iwasa M, Hara N,
Hepatol Res. 2017 Nov
8.
Abstract
Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?
Premkumar M, Grover GS, Dhiman RK.
J Clin Exp Hepatol.
2017 Sep;7(3):253-261
Abstract
Recent advancement of Direct-acting antiviral agents (DAAs) in Hepatitis C
therapy.
Das D, Pandya M.
Mini Rev Med Chem. 2017
Sep 12.
Abstract
Editorial: Direct Antiviral Agents Eliminate the Age Barrier
to Treatment of Chronic Hepatitis C
Koff RS.
Am J Gastroenterol.
2017 Sep;112(9):1410-1411
Abstract
High HCV cure rates for people who use drugs treated with direct
acting antiviral therapy at an urban primary care clinic.
Norton BL, Fleming J, Bachhuber MA, et al
Int J Drug Policy.
2017 Aug 12
Abstract
Systematic review: cost-effectiveness of direct-acting
antivirals for treatment of hepatitis C genotypes 2-6
He T, Lopez-Olivo MA, Hur C, Chhatwal J.
Aliment Pharmacol Ther.
2017 Aug
24
Abstract |
|
Hepatitis C virus-related symptoms, but not quality of life, were improved
by treatment with direct-acting antivirals.
Ichikawa T, Miyaaki H, Miuma S, et al
Hepatol Res.
2017 Aug 24
Abstract
Improving pharmacotherapy outcomes in patients with hepatitis C virus
infection treated with direct-acting antivirals: The GRUviC project.
Chamorro-de-Vega E, Rodriguez-Gonzalez CG,
Int J Clin Pract.
2017 Aug;71
Abstract
High HCV cure rates for people who use drugs treated with direct acting
antiviral therapy at an urban primary care clinic.
Norton BL, Fleming J, Bachhuber MA
Int J Drug Policy.
2017 Aug 1|
Abstract
Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus
Infection in Organ Transplantation.
Colpitts CC, Chung RT, Baumert TF.
ACS Infect Dis.
2017 Aug 16.
Abstract
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy:
A systematic review, meta-analyses, and meta-regression.
Waziry R, Hajarizadeh B, Grebely J,
et al
J Hepatol. 2017 Aug 9
Abstract
Portal vein thrombosis after hepatitis C eradication with direct acting
antiviral therapy.
Stine JG, Prakash S, Northup PG
Liver Int.
2017 Aug 7.
Abstract
The majority of hepatitis C patients treated with direct
acting antivirals are at risk for relevant drug-drug interactions.
Smolders EJ, Berden FA, de Kanter CT,
United European Gastroenterol J.
2017 Aug;5(5):648-657.
Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in
Patients with Hepatitis C Virus-associated Cirrhosis.
Lens S, Alvarado E, Marińo Z,et
al
Gastroenterology.
2017 Jul 19
Abstract
HCV-infected
and HIV/HCV co-infected individuals treated with direct-acting antivirals:
to what extent do they differ?
Bruno G, Saracino A, Scudeller L,
et al
Int J Infect Dis. 2017
Jul 17
Abstract
Direct-acting antivirals for hepatitis C virus in patients on maintenance
dialysis.
Fabrizi F, Donato FM, Messa P.
Int
J Artif Organs. 2017 Jul 8:
Abstract
Drug Interactions in HIV-Infected Patients Treated for Hepatitis C.
Soriano V, Labarga P, Fernandez-Montero JV,
et al.
Expert Opin Drug Metab Toxicol.
2017 Jul
Abstract
Direct-acting antivirals for hepatitis C virus in patients on maintenance
dialysis.
Fabrizi F, Donato FM, Messa P.
Int J Artif Organs. 2017
Jul 8:
Abstract
Application of Exposure-Response Analyses to Establish the Pharmacodynamic
Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen
for the Treatment of HCV Infection.
Polepally AR, Wang H,
Marroum PJ,
AAPS J.
2017 Jul 6.
Abstract
Societal perspectives and patient/public involvement in DAAs
coverage of hepatitis C treatment in the U.S.
Liu X, Lee JL, Yoo JW.
Clin
Gastroenterol Hepatol.
2017 Jun 9.
Abstract
Direct-Acting Antiviral Treatment against
Hepatitis C Virus infection in HIV-Infected Patients - "En route
for eradication"?
Pradat P, Pugliese P, Poizot-Martin I, et al
J Infect.
2017 Jun 1
Abstract
Resistance Mechanisms in Hepatitis C Virus:
implications for Direct-Acting Antiviral Use.
Bagaglio S, Uberti-Foppa C, Morsica G.
Drugs.
2017 May 12.
Abstract
The Direct-Acting Antivirals for Hepatitis C Virus and the Risk
for Hepatocellular Carcinoma.
Chinchilla-López P, Qi X, Yoshida EM, Méndez-Sánchez N.
Ann Hepatol.
2017 May - Jun 2017;16(3):328-330.
Abstract
Cost-effectiveness of the highly effective direct-acting
antivirals in the treatment of chronic hepatitis C in Hong Kong.
Lo AO, Chan HL, Wong VW, Wong GL.
J Gastroenterol Hepatol.
2017 May;32(5):1071-1078.
Abstract
Direct-acting antivirals: the endgame for hepatitis C?
D'Ambrosio R, Degasperi E, Colombo M, Aghemo A.
Curr Opin Virol.
2017 Apr 15;24:31-37.
Abstract
Clinical efficacy and tolerability of direct-acting antivirals in elderly
patients with chronic hepatitis C.
Sherigar JM, Gayam V, Khan A, et al.
Eur J Gastroenterol Hepatol.
2017 Mar 24.
Abstract
Oral Direct-Acting Agent Therapy for Hepatitis C Virus
Infection: A Systematic Review.
Falade-Nwulia O, Suarez-Cuervo C,
et l
Ann Intern Med.
2017 Mar 21.
.
Abstract
Considerations on bringing warehoused HCV patients into
active care following interferon-free, direct-acting antiviral drug
approval.
Palak A, Livoti C, Audibert C.
Postgrad Med.
2017 Mar 9.
Abstract
Transformation of hepatitis C antiviral treatment in a national healthcare
system following the introduction of direct antiviral agents.
Moon AM, Green PK, Berry K, Ioannou GN.
Aliment
Pharmacol Ther.
2017 Mar 8.
Abstract
Pharmacokinetic Considerations for Combining Antiretroviral
Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction
Treatment Medications.
Bednasz CJ, Venuto CS, Ma Q, Morse GD.
Clin Pharmacol Drug Dev.
2017 Mar;6(2):135-139.
Abstract
FULL-TEXT ARTICLE
Real-life data on potential drug-drug interactions in patients with chronic
hepatitis C viral infection undergoing antiviral therapy with
interferon-free DAAs in the PITER Cohort Study.
Kondili LA, Gaeta GB, Ieluzzi D, et al
PLoS One.
2017 Feb 28;12(2):e0172159
Paper
FULL-TEXT
ARTICLE
Novel
emerging treatments for hepatitis C infection: a fast-moving pipeline.
Kardashian AA, Pockros PJ.
Therap Adv Gastroenterol. 2017
Feb;10(2):277-282.
Paper
Direct-acting antivirals are effective for chronic hepatitis C treatment in
elderly patients: a real-world study of 17 487 patients.
Su F, Beste LA, Green PK, Berry K, Ioannou GN.
Eur J Gastroenterol Hepatol.
2017 Feb 13.
Abstract
Applications of Computer-Aided Approaches in The Development of Hepatitis C
Antiviral Agents.
Ganesan A, Barakat K.
Expert Opin Drug Discov. 2017
Feb 4
Abstract
Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C
Virus Therapy with Direct-Acting Antivirals.
Prenner S, VanWagner LB, Flamm SL
J Hepatol.
2017 Feb 1..
Abstract
FULL-TEXT
ARTICLE
Baseline quasispecies selection and novel mutations contribute to emerging
resistance-associated substitutions in hepatitis C virus after direct-acting
antiviral treatment.
Kai Y, Hikita H, Morishita N, et al
Sci Rep.
2017 Jan 30;7:41660.
.
Paper
Zika viral polymerase
inhibition using anti-HCV
drugs both in market and
under clinical trials.
Elfiky AA.
J Med Virol.
2016
Dec;88(12):2044-2051
Abstract
Limiting the access to
direct-acting antivirals
against HCV: an ethical
dilemma.
Gentile I, Maraolo AE, Niola
M,
et
al
Expert Rev Gastroenterol
Hepatol.
2016
Nov;10(11):1227-1234
Abstract
Hepatitis C Virus and
Antiviral Drug Resistance.
Kim S, Han KH, Ahn SH.
Gut Liver.
2016 Nov 15;10(6):890-895.
Abstract
All-oral direct-acting
antiviral therapy in
HCV-advanced liver disease
is effective in real-world
practice: observations
through HCV-TARGET database.
Reddy KR, Lim JK, Kuo A,
et al
Aliment Pharmacol Ther.
2016 Oct 28.
Abstract
Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related
Liver Cirrhosis.
Toshikuni N.
Gut Liver. 2016 Nov 14.
Abstract
FULL-TEXT ARTICLE
Treatment Selection Choices
Should Not Be Based on
Benefits or Costs Alone: A
Head-to-Head Randomized
Controlled Trial of
Antiviral Drugs for
Hepatitis C.
Davitkov P, Chandar AK,
Hirsch A,
PLoS One.
2016 Oct 14;11(10):e0163945.
Paper
Oral Combination Therapies
for Hepatitis C Virus
Infection: Successes,
Challenges, and Unmet Needs.
Naggie S, Muir AJ.
Annu Rev Med.
2016 Sep 23.
Abstract
Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype
1 Infection are Cost Saving.
Chhatwal J, He T, Hur C, Lopez-Olivo MA.
Clin Gastroenterol Hepatol.
2016 Sep 17.
Abstract
Direct-acting antivirals in hepatitis C virus (HCV)-infected
and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L, Lai A,
Calvi E, et al
HIV Med.
2016 Aug 1.
Abstract
Preclinical Assessment of the Clinical Cardiac Drug-Drug Interaction
Associated with the Combination of HCV-NI Antivirals and Amiodarone.
Regan CP, Morissette P, Regan HK,
et al
Hepatology.
2016 Jul 30.
Abstract
Safety of interferon-free therapies for chronic hepatitis C:
a network meta-analysis.
Ferreira VL, Assis Jarek NA, et al
J Clin Pharm Ther. 2016
Jul 21.
Abstract
FULL-TEXT ARTICLE
Hepatitis C
virus cures after direct acting antiviral-related drug-induced liver injury:
Case report.
Hasin Y, Shteingart S, Dahari H,
et al
World J Hepatol.
2016 Jul 18;8(20):858-62.
Paper
The time and cost investment required to obtain and initiate direct-acting
antiviral therapy.
Loy V, Benyashvili T, Adams W, Pavkov D,
et al
Antivir Ther. 2016 Jul
14
Abstract
Optimization of triple therapy for patients with chronic hepatitis C: a
systematic review.
Pecoraro V, Cariani E, Villa E, Trenti T.
Eur J Clin Invest.
2016 Jul 4.
Abstract
Rate and predictors of treatment failure to all-oral HCV
regimens outside clinical trials.
Arias A, Aguilera A, Soriano V,
et al
Antivir Ther. 2016 Jun 24..
Abstract
FULL-TEXT ARTICLE
Changes in
serum transforming growth factor-β1 levels in chronic hepatitis C patients
under antiviral therapy.
Kotsiri I, Hadziyannis E, Georgiou A, Papageorgiou MV,
et al
Ann Gastroenterol.
2016 Jan-Mar;29(1):79-84.
Paper
Systematic Review of Modelling Approaches for the Cost Effectiveness of
Hepatitis C Treatment with Direct-Acting Antivirals.
Chhatwal J, He T, Lopez-Olivo MA.
Pharmacoeconomics. 2016 Jan 9.
Abstract
FULL-TEXT ARTICLE
Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naďve
Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.
Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, et al
PLoS One. 2015 Dec 31;10(12):e0145953
Paper |
FULL-TEXT ARTICLE
Factors
associated with the response to interferon-based antiviral therapies for chronic
hepatitis C.
Enomoto H, Nishiguchi S.
World J Hepatol. 2015 Nov 18;7(26):2681-2687
Paper
Resistance of Hepatitis C Virus to Inhibitors: Complexity and
Clinical Implications.
Perales C, Quer J,
Gregori J, et al
Viruses. 2015
Nov 6;7(11):5746-5766.
Abstract
Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.
Vizuete J,
Hubbard H, Lawitz E.
Clin Liver Dis. 2015
Nov;19(4):707-16.
.
Abstract
Regimens for the Hepatitis C Treatment-Naive Patient.
Ayoub WS, Tran TT.
Clin Liver Dis.
2015 Nov;19(4):619-27.
Abstract
Abstract
All-oral interferon-free treatments: The end of hepatitis C virus story, the
dream and the reality.
Adinolfi LE, Guerrera B.
World J Hepatol.
2015 Oct 8;7(22):2363-8.
Abstract
Interferon-Free Therapy for Hepatitis C in Liver
Transplant Recipients.
Ueda Y, Uemoto S.
Transplantation.
2015 Sep 2.
Abstract
Successful treatment of chronic hepatitis C with triple
therapy in an opioid agonist treatment program.
Litwin AH,
Soloway IJ, Cockerham-Colas L, et al
Int J Drug Policy.
2015 Aug 20.
Abstract |
| |
FULL-TEXT ARTICLE
Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation
Direct-Acting Agents.
Woodrell C, Weiss J, Branch A, et al
J Addict Med. 2015 Aug
17.
Paper |
Direct-acting antiviral drugs for the treatment of chronic
hepatitis c virus infection: Interferon free is now.
Florian J, Mishra P, Arya V, et al
Clin Pharmacol Ther. 2015 Jul
14.
Abstract
Hepatitis C Virus Drug Resistance-associated Substitutions:
State of the Art Summary.
Lontok E, Harrington P, Howe A,
et al
Hepatology. 2015 Jun 10.
Abstract
Interferon-free,
direct-acting antiviral therapy for chronic hepatitis C.
Gutierrez JA, Lawitz EJ, Poordad F.
J Viral Hepat. 2015 Jun 17.
.
Abstract
Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular
Carcinoma.
Hsu YC, Wu CY, Lin JT.
Semin Oncol. 2015 Apr;42(2):329-338.
Abstract
Cost-Effectiveness of Novel Regimens for the Treatment of
Hepatitis C Virus.
Najafzadeh M, Andersson K, Shrank
, et al
Ann Intern Med. 2015 Mar 17.
Abstract
A Review of Drug Interactions With Direct-Acting Antivirals for Hepatitis C:
Implications for HIV and Transplant Patients.
Burgess S, Partovi N, Yoshida EM,
et al
Ann Pharmacother. 2015 Mar 13..
Abstract
Revolution in hepatitis C antiviral therapy.
Sadler MD, Lee SS.
Br Med
Bull. 2015 Feb 13.
Abstract
The changing face of Hepatitis C: Recent Advances on HCV
Inhibitors Targeting NS5A.
Rai D, Wang L, Jiang X, et al
Curr Med Chem. 2015 Feb 9.
Abstract
Hepatitis C therapy: Looking toward interferon-sparing
regimens.
Au TH, Destache CJ, Vivekanandan
R.
J Am Pharm Assoc (2003). 2015 Feb 6:e72-e8
Paper
Prescription of new HCV-drugs - what has to be considered
judicially.
Mauss S.
Z Gastroenterol. 2015 Jan;53(1):43-5.
Abstract
Beyond interferon: rationale and prospects for newer
treatment paradigms for chronic hepatitis C.
Cortez KJ, Kottilil S.
Ther Adv Chronic Dis. 2015
Jan;6(1):4-14.
Abstract
Drug interactions with new hepatitis C oral drugs.
Soriano V, Labarga P, Barreiro P,
et al
Expert Opin Drug Metab Toxicol. 2015
Jan 2:1-9.
Abstract
Current and future HCV therapy: do we still need other
anti-HCV drugs?
Petta S, Craxě A.
Liver Int. 2015 Jan;35 Suppl
s1:4-10.
Abstract
Importance of very early HCV RNA kinetics for prediction of
treatment outcome of highly effective all oral direct acting antiviral
combination therapy.
Sarrazin C,
Wedemeyer H, Cloherty G,
et al
J Virol Methods. 2014 Dec 18. pii:
S0166-0934(14)00474-1
Abstract
Naturally occurring dominant drug resistance mutations occur
infrequently in the setting of recently acquired hepatitis C.
Applegate TL, Gaudieri S,
Plauzolles A, et al
Antivir Ther. 2014 Aug 8.
Abstract
Antiviral treatment of hepatitis C.
Feeney ER, Chung RT.
BMJ. 2014 Jul 7;349:g3308.
Abstract
Update on hepatitis C virus
resistance to direct-acting antiviral agents.
Poveda E, Wyles DL, Mena A, et al
Antiviral Res.
2014 Jun 6.
Abstract
FULL-TEXT ARTICLE
Synergy of entry inhibitors with direct-acting antivirals
uncovers novel combinations for prevention and treatment of
hepatitis C.
Xiao F, Fofana I, Thumann C, Mailly L, et al
Gut.
2014 May 21.
Paper
HCV direct-acting antiviral agents: the best interferon-free
combinations.
Schinazi R, Halfon P, Marcellin P, Asselah T.
Liver Int. 2014 Feb;34 Suppl 1:69-78.
Minimum costs for producing Hepatitis C Direct
Acting Antivirals, for use in large-scale treatment access
programs in developing countries
Hill A, Khoo S, Fortunak J, et al
Clin Infect Dis.
2014 Jan 6.
Abstract
FULL-TEXT ARTICLE
Antiviral treatment of hepatitis C virus infection and factors
affecting efficacy.
Zhu Y, Chen S.
World J Gastroenterol.
2013 Dec 21;19(47):8963-8973.
Paper
Impact of Interferon Free Regimens on Clinical
and Cost Outcomes for Chronic Hepatitis C Genotype 1 Patients.
Younossi ZM, Singer ME, Mir HM,
et al
J Hepatol. 2013 Nov
19.
Abstract
Predictors for dose reduction of antiviral therapy in older
patients infected with hepatitis C virus: a meta-regression analysis.
Zhou H, Luo H, Xiao S, et al
Eur J Clin Microbiol Infect Dis.
2013 Nov 6.
Abstract
Interferon-Free
Regimens for Hepatitis C: Combine and Conquer.
Martel-Laferričre V, Bichoupan
K, Dieterich DT.
BioDrugs. 2013 Oct 30.
Abstract
The clinical significance of drug-drug interactions in the era of direct-acting
anti-viral agents against chronic hepatitis C virus.
Maasoumy B, Port K, Calle Serrano B, et al
Aliment Pharmacol Ther.
2013 Oct 16
Abstract
Novel Therapeutic Approaches for Hepatitis C.
Au JS, Pockros PJ.
Clin Pharmacol Ther. 2013
Oct 14.
Abstract
Is there sufficient evidence to recommend antiviral therapy
in hepatitis C?
van der Meer AJ, Wedemeyer H, Feld
JJ, et al
J Hepatol. 2013 Aug 20.
Abstract
Drug-drug interactions during antiviral therapy for chronic
hepatitis C.
Kiser JJ, Burton JR Jr,
Everson GT
Nat Rev Gastroenterol Hepatol.
2013 Jul 2.
Abstract
Cost-Effectiveness Analysis of Direct-Acting Antiviral
Therapy for Treatment-Naďve Patients with Chronic Hepatitis C Genotype 1
Infection in the Veterans Health Administration.
Chan K, Lai MN, Groessl EJ,
et al
Clin Gastroenterol Hepatol. 2013 May 22.
Abstract
A review of pharmacological interactions between HIV or
hepatitis C virus medications and opioid agonist therapy: implications and
management for clinical practice.
Bruce RD, Moody DE, Altice FL,
et al
Expert Rev Clin Pharmacol. 2013
May;6(3):249-69.
Abstract
Earlier Sustained Virologic Response Endpoints for Regulatory Approval and Dose
Selection of Hepatitis C Therapies.
Chen J, Florian J, Carter W, Fleischer RD,
et al
Gastroenterology.
2013 Mar 4.
Abstract
FULL-TEXT ARTICLE
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C
Virus Infection From AASLD 2012: The 63rd Annual Meeting of the American
Association for the Study of Liver Diseases November 9-13, 2012 • Boston,
Massachusetts
[No authors listed]
Gastroenterol Hepatol (N Y).
2013 Jan;9(1 Suppl 1):1-20.
Paper |
Antiviral resistance and direct-acting antiviral agents for HCV.
Aloia AL, Locarnini S, Beard MR.
Antivir Ther.
2012;17(6 Pt B):1147-62.
Abstract
Future perspectives: towards interferon-free regimens for HCV.
Gane E.
Antivir Ther. 2012;17(6 Pt B):1201-10.
Abstract
Highly active anti-hepatitis C therapy: seven lessons from HIV.
Thomas DL.
Antivir Ther. 2012;17(6 Pt B):1183-8.
Abstract
HCV Variants with Decreased Sensitivity to Direct Acting
Antivirals Were Rarely Observed in DAA-Naive Patients Prior to Treatment.
Bartels DJ, Sullivan
JC, Zhang EZ, et al
J Virol. 2012 Nov 14.
Abstract |
The changing face of hepatitis C in the new era of direct-acting
antivirals.
Soriano V, Labarga P,
Fernández-Montero JV, et al
Antiviral Res. 2012 Nov 9.
Abstract
FULL-TEXT
PDF ARTICLE
New therapeutic options for HCV infection in the monoclonal antibody era.
Sautto GA, Diotti RA, Clementi M.
New Microbiol. 2012
Oct;35(4):387-97.
Paper
New hepatitis C virus drug discovery strategies and model
systems.
Hussain S, Barretto N, Uprichard SL.
Expert Opin Drug Discov.
2012 Sep;7(9):849-59.
Abstract
aMximizing opportunities and avoiding mistakes in triple therapy for hepatitis
C virus.
Barritt AS 4th, Fried MW
Gastroenterology.
2012 May;142(6):1314-1323.
Abstract
FULL-TEXT ARTICLE
New antiviral agents for hepatitis C.
Pawlotsky JM.
F1000 Biol Rep.
2012;4:5..
Paper |
Antiviral Drugs and the Treatment of
Hepatitis C.
Jalali Z, Rockstroh JK.
Curr HIV/AIDS Rep.
2012 Feb
22
Abstract
Antiviral strategies in hepatitis C virus
infection.
Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.
J Hepatol.
2012;56 Suppl:S88-S100
Abstract |
Direct acting antivirals for the treatment of chronic hepatitis
C: one pill a day for tomorrow.
Asselah T, Marcellin P.
Liver Int.2012 Feb;32 Suppl
1:88-102.
.
Abstract
FULL-TEXT
ARTICLE
The therapeutic approaches for hepatitis C virus: protease
inhibitors and polymerase inhibitors.
Kwo PY, Vinayek R.
Gut Liver.
2011 Dec;5(4):406-17
Paper |
Provisional Guidance on the Use of Hepatitis
C Virus Protease Inhibitors for Treatment of Hepatitis C
in
HIV-Infected Persons.
Thomas DL, Bartlett JG, Peters MG,
et al
Clin Infect Dis.
2011 Dec 14
Abstract
Recent advance in antiviral drugs for hepatitis C.
Liu J, Shi S, Zhuang H, Luo G.
Zhong Nan Da Xue Xue Bao Yi Xue Ban.
2011 Nov;36(11):1025-36.
Abstract |
Mechanisms Involved in the Development of Chronic Hepatitis
C as Potential Targets of Antiviral Therapy.
Jackowiak P, Figlerowicz M,
Kurzyńska-Kokorniak A, Figlerowicz M.
Curr Pharm Biotechnol. 2011 Sep
9.
Abstract
Oral combination therapy: Future hepatitis C virus
treatment?
Hézode C.
J Hepatol.
2011 May
Abstract
Current drug discovery strategies for treatment of hepatitis C virus infection.
Cheng KC, Gupta S, Wang H,
et al
J Pharm Pharmacol. 2011
Jul;63(7):883-92.
Abstract
Hepatitis C virus Resistance to Protease
Inhibitors.
Halfon P, Locarnini S.
J Hepatol.
2011 Jan 29.
Abstract
Mixing the right hepatitis C inhibitor cocktail.
Gelman MA, Glenn JS.
Trends Mol Med.
2010 Nov 22.
Abstract |
Susceptibility of Treatment-Naive HCV Clinical
Isolates to HCV Protease Inhibitors.
Bae A, Sun SC, Qi X,
et al
Antimicrob Agents Chemother.
2010 Sep 20
Abstract |
Prophylactic antidepressant treatment in patients
with hepatitis C on antiviral therapy:
a double-blind, placebo-controlled trial.
Morasco BJ, Loftis JM, Indest DW,
et
al
Psychosomatics.
2010 Sep;51(5):401-8.
Abstract |
Viral response to specifically targeted antiviral therapy for
hepatitis C
and the implications
for treatment success.
Cooper C.
Can J Gastroenterol.
2010 Jun;24(6):385-90
Abstract |
New directly acting antivirals for hepatitis C:
potential for interaction with antiretrovirals.
Seden K, Back D, Khoo S.
J Antimicrob
Chemother.
2010 Mar 23
Abstract |
|
|
|
|
|
|
|
|
|
Journal
Papers, Abstracts, and Commentaries
Conference Reports, Abstracts, and
Posters
|
Journal Papers, Abstracts, and Commentaries
|
| |
Daclatasvir and Sofosbuvir With or Without Ribavirin in
Liver Transplant Recipients: A Single-Center Real-World Study.
Mucenic M, Bandeira de Mello Brandao A, et al
Transplant Proc.
2018 Apr;50(3):769-771
Abstract
FULL-TEXT ARTICLE
Daclatasvir plus asunaprevir in treatment-naďve patients with hepatitis
C virus genotype 1b infection.
Wei L, Wang FS, Zhang MX, et al
World J Gastroenterol.
2018 Mar 28;24(12):1361
Paper
Treatment of hepatitis C virus infection for adults and children:
updated Swedish consensus guidelines 2017.
Lagging M, Wejstĺl R, Duberg AS,
Infect Dis (Lond). 2018
Mar 1:1-15.
Abstract
Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese
Patients with Chronic Hepatitis C Virus Genotype 1b.
Liu Y, Wang Z, Tobe RG, et al
Clin Drug Investig.
2018 Feb 7.
Abstract
Daclatasvir Plus Asunaprevir for the Treatment of
Patients with Hepatitis C Virus Genotype 1b Infection: Real-World
Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.
Lee HW, Oh SR, Kim DY, et al
Gut Liver. 2018 Feb
8.
Abstract
Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.
Gandhi Y, Eley T, Fura A,
Clin Pharmacokinet.
2018 Jan 20
Abstract
Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic
treatment for hepatitis C in patients with eGFR <30 ml/min.
Goel A, Bhadauria DS, Kaul A,
et al
Nephrology (Carlton).
2018 Jan 12.
Abstract
Efficacy of daclatasvir-based quadruple therapy in
nonresponder patients infected by hepatitis C virus genotype 4: the ANRS
HC32 QUATTRO study.
Roulot D, Thibault V, Laforest C,
Eur J Gastroenterol Hepatol.
2017 Dec 21.
Abstract
FULL-TEXT ARTICLE
Rapid Changes in Serum Lipid Profiles during Combination Therapy with
Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus
Genotype 1b.
Chida T, Kawata K, Ohta K, Matsunaga E,
et al
Gut Liver.
2017 Dec 8
Paper
Efficacy and Safety of Simeprevir or Daclatasvir in
Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4
Infection.
Babatin MA, Alghamdi AS, Albenmousa A,
et al
J Clin Gastroenterol.
2017 Aug 1.
Abstract
FULL-TEXT ARTICLE
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus
sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus.
McEwan P, Webster S, Ward T,
Cost Eff Resour Alloc.
2017 Jul 21;
Paper
Efficacy and safety of daclatasvir-based antiviral therapy in HCV
recurrence after liver transplantation. Role of cirrhosis and genotype
3. A multi-centre cohort study.
Salcedo M, Prieto M, Castells L, et al
Transpl Int. 2017 Jun 13
Abstract
Pooled analysis of HCV genotype 1 resistance-associated substitutions in
NS5A, NS3 and NS5B pre- and post-treatment with 12 weeks of
daclatasvir, asunaprevir and beclabuvir.
McPhee F, Hernandez D, Zhou N, et al.
Antivir Ther. 2017 Jun 8.
Abstract
Daclatasvir/Asunaprevir/Beclabuvir (DCV-TRIO),
All-Oral, Fixed-Dose Combination for Patients With Chronic HCV
Genotype 1.
Kao JH, Yu ML, Peng CY, et al
J Gastroenterol Hepatol.
2017 Mar 31.
Abstract
Cost-effectiveness of combination daclatasvir-sofosbuvir
for the treatment of genotype 3 chronic hepatitis c infection in the
United States.
Saint-Laurent Thibault C, Moorjaney D,
et al
J Med Econ. 2017
Mar 15:1-20.
Abstract
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without
Ribavirin, in HIV/HCV Co-Infected Patients With Advanced Liver
Disease in a French Early-Access Cohort.
Lacombe K, Fontaine H, Dhiver C,
J Acquir Immune Defic Syndr.
2017 Mar 6.
Abstract
Daclatasvir and asunaprevir treatment in patients with
severe liver fibrosis by HCV genotype 1b infection: Real world data.
Ishigami M, Hayashi K, Honda
T, et al
J Gastroenterol Hepatol. 2017 Mar 4.
Abstract
FULL-TEXT
ARTICLE
An HCV-positive recipient of an HCV-positive donor liver
successfully treated before and immediately after liver transplant with
daclatasvir, sofosbuvir, and ribavirin.
Poordad F, Lawitz E, Gutierrez JA, et al
Clin Case Rep. 2017 Feb
3;5(4):371-375
Paper
The efficacy and safety of dual oral therapy with daclatasvir and
asunaprevir for genotype 1b in Japanese real-life settings.
Sezaki H, Suzuki F, Hosaka T, Akuta N, et al
Liver Int. 2017 Feb 8.
Abstract
Sofosbuvir in combination with daclatasvir in liver transplant
recipients with HCV infection: A systematic review and meta-analysis.
Liao H, Tan
P, Zhu Z, Yan X, Huang J.
Clin Res
Hepatol Gastroenterol.
2017 Jan 9
Abstract
FULL-TEXT ARTICLE
Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients
Unresponsive to Daclatasvir plus Asunaprevir Treatment.
Inoue J, Kanno A, Wakui Y, Miura M, et al
Tohoku J Exp Med.
2017;241(1):21-28.
Paper
Impact of resistance-associated variant dominancy on treatment in
patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
Ikeda H, Watanabe T,
Okuse C, et al
J Med Virol. 2017
Jan;89(1):99-105.
Abstract
Favorable efficacy of daclatasvir plus asunaprevir in treatment of
elderly Japanese patients infected with HCV genotype 1b aged 70
and older.
Akuta N, Sezaki H, Suzuki F,
et al
J
Med Virol. 2017
Jan;89(1):91-98.
Abstract
Real-World Experience With Daclatasvir Plus Sofosbuvir ± Ribavirin for Post-Liver Transplant HCV Recurrence and Severe Liver Disease
Herzer K, Welzel TM, Spengler U, et al
Transpl Int. 2016 Dec 24
Abstract
Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
McPhee F, Hernandez D, Zhou N.
Antivir Ther. 2016 Dec 23
Abstract
Real world data of daclatasvir and asunaprevir combination therapy for HCV
genotype 1b infection in patients with renal dysfunction.
Ishigami M, Hayashi K, Honda T, et al
Clin Gastroenterol Hepatol.
2016 Dec 21
Abstract
Daclatasvir Prevents Hepatitis C Virus by Blocking Transfer of Viral Genome to Assembly Sites.
Boson B, Denolly S, Turlure F, et al
Gastroenterology. 2016 Dec 5.
Abstract
A Review of Daclatasvir Drug-Drug Interactions.
Garimella T, You X, Wang R,
et al
Adv
Ther. 2016
Nov;33(11):1867-1884
Abstract
FULL-TEXT ARTICLE
Daclatasvir combined with peginterferon-α and ribavirin for the
treatment of chronic hepatitis C: a meta-analysis.
Peng
Q, Li K, Cao MR, et al
Springerplus. 2016
Sep 15;5(1):1569.
Paper
Safety and efficacy of dual therapy with daclatasvir and asunaprevir for
older patients with chronic hepatitis C.
Morio R, Imamura M, Kawakami
Y, et al
J Gastroenterol.
2016 Sep 8
Abstract
Characterization of NS5A polymorphisms and their impact on response
rates in patients with HCV genotype 2 treated with
daclatasvir-based regimens.
Zhou
N, Han Z, Hartman-Neumann S,
J
Antimicrob Chemother.
2016 Sep 7
Abstract
Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis
C genotype 1b: a case report.
Pi SN, Chen YP.
Nan Fang Yi Ke Da Xue Xue Bao.
2016
Abstract
Daclatasvir: A Review in Chronic Hepatitis C.
Keating GM.
Drugs. 2016 Aug 22.
Abstract
Real-World Efficacy and Safety of Daclatasvir and Asunaprevir Therapy
for Hepatitis C Virus-Infected Cirrhosis Patients.
Morio K, Imamura M, Kawakami
Y,
et a;
J Gastroenterol Hepatol.
2016 Aug 11
Abstract
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese
patients with HCV genotype 1 infection.
Toyota J, Karino Y, Suzuki
F, Ikeda F, et al
J
Gastroenterol. 2016
Aug 9.
Abstract
Hyperbilirubinemia without Transaminitis during Combined Therapy with
Daclatasvir and Asunaprevir.
Baba H, Tajiri K, Nagata K, Kawai K, Minemura M, Sugiyama T.
Case Rep Gastroenterol. 2016
Jul 8;10(2):352-9.
Abstract
Daclatasvir plasma level and resistance selection in HIV patients
with HCV cirrhosis treated with daclatasvir, sofosbuvir and ribavirin.
Parisi SG, Loregian A, Andreis S,
Int J Infect Dis.
2016 Jul 1.
Abstract
Safety and efficacy of daclatasvir in the management of patients with
chronic hepatitis C.
Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V.
Ann Gastroenterol. 2016
Jul-Sep;29(3):282-96.
Abstract
Impact
of resistance-associated variant dominancy on treatment in patients with
HCV genotype 1b receiving daclatasvir/asunaprevir.
Ikeda H,
Watanabe T, Okuse C, Matsumoto N,
et al
J Med Virol. 2016 Jun 22
Abstract
A case of acute hepatitis B in a chronic hepatitis C
patient after daclatasvir and asunaprevir combination therapy: hepatitis
B virus reactivation or acute self-limited hepatitis?
Hayashi K, Ishigami M, Ishizu Y,
et
al
Clin J Gastroenterol. 2016
Jun 21.
Abstract
A UHPLC-MS/MS method for the quantification of direct antiviral agents
simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir,
ombitasvir and paritaprevir, together with ritonavir, in human plasma.
Ariaudo A, Favata F, De Nicolň A.
et al
J Pharm Biomed Anal. 2016
Jun 5;125:369-75.
Abstract
Multicentre experience using daclatasvir and sofosbuvir to treat
hepatitis C recurrence after liver transplantation - The CO23 ANRS
CUPILT study.
Coilly A, Fougerou-Leurent C, de Ledinghen V, et al
J Hepatol. 2016
Jun 1
Abstract
Sixty milligram daclatasvir is the right dose for hepatitis C virus
treatment in combination with etravirine and darunavir/ritonavir.
Smolders EJ, Kanter CT, Grintjes K,
et al
AIDS.
2016 Jun 1;30(9):1491-3.
Abstract
Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype
1-Infected Patients in Japan.
Kanda T, Yasui S, Nakamura M, Suzuki E,
Int J Med Sci. 2016 May
12;13(6):418-23. doi
Abstract
Effectiveness and safety of daclatasvir plus asunaprevir for HCV
genotype 1b patients aged 75 and over with or without cirrhosis.
Ogawa E, Furusyo N, Yamashita N,
et al
Hepatol Res.
2016 May 3.
Abstract
Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for
Chronic Hepatitis C Virus Genotype 1b -Infected Patients on
Hemodialysis.
Miyazaki R, Miyagi K.
Ther Apher Dial. 2016 Apr
21.
Abstract
Combination therapy with daclatasvir and asunaprevir for dialysis
patients infected with hepatitis C virus.
Sato
K, Yamazaki Y, Ohyama T,
et al
World
J Clin Cases.
2016 Mar 16;4(3):88-93.
Abstract
Synthesis of isotopically labeled
daclatasvir for use in human clinical studies.
Easter JA, Burrell RC, Bonacorsi SJ Jr.
J Labelled Comp Radiopharm.
2016 Mar 10
Abstract
Sustained virological response after a 17-day treatment with daclatasvir
plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype
1b and null response for peginterferon ribavirin therapy.
Sato A, Ishii T, Adachi K,
et al
Clin J Gastroenterol.
2016 Feb 20.
Abstract
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir
and asunaprevir) for chronic hepatitis C virus genotype 1 infection in
patients on hemodialysis.
Toyoda H, Kumada T, Tada T,
et al
J Gastroenterol.
2016 Feb 12.
Abstract
Efficacy and safety of daclatasvir and asunaprevir combination therapy
in chronic hemodialysis patients with chronic hepatitis
C.Suda
G, Kudo M, Nagasaka A,
et al
J Gastroenterol.
2016 Jan 14.
Abstract
Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With
Advanced Cirrhosis or Post-Liver Transplant Recurrence.
Poordad F, Schiff ER, Vierling JM,
Hepatology. 2016 Jan 11
Abstract
Daclatasvir Plus Asunaprevir for HCV Genotype 1b
Infection in Patients With or Without Compensated Cirrhosis: A Pooled
Analysis.
Kao JH, Jensen
DM, Manns MP, et al
Liver Int. 2015 Dec 18.
Abstract
Improvement of renal dysfunction in a patient with HCV-related liver
cirrhosis by daclatasvir and asunaprevir combination therapy: A case
report.
Tsuge M, Hiramatsu A, Shinohara F, et al
Hepatol Res. 2015
Nov 27
Abstract
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection
with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a
Focus on the Prevention of Occurrence and Recurrence of Hepatocellular
Carcinoma.
Sugimoto K, Kim SR, Kim SK,et al
Oncology.
2015 Nov;89 Suppl 2:42-46
Abstract
The safety of daclatasvir for the treatment of hepatitis C.
Jafri SM, Gordon SC.
Expert Opin Drug Saf.
2015 Nov;14(11):1787-1797.
Abstract
Combination therapies with daclatasvir and asunaprevir on
NS3-D168 mutated HCV in human hepatocyte chimeric mice.
Kan H, Hiraga
N, Imamura M, et al
Antivir Ther. 2015 Nov 12.
Abstract
Daclatasvir: A NS5A Replication Complex Inhibitor for
Hepatitis C Infection.
Smith MA, Regal RE, Mohammad RA.
Ann Pharmacother. 2015 Oct 20.
Abstract
Daclatasvir + Asunaprevir + Beclabuvir ± Ribavirin for
Chronic HCV Genotype 1-Infected Treatment-Naive Patients.
Everson GT,
Sims KD, Thuluvath PJ, et al
Liver Int.
2015 Oct 16.
Abstract
Multi-scale model for hepatitis C viral load kinetics
under treatment with direct acting antivirals.
Clausznitzer D,
Harnisch J, Kaderali L.
Virus Res. 2015 Sep 23.
Abstract
Randomized controlled trial of the NS5A inhibitor
daclatasvir plus peginterferon and ribavirin for HCV genotype-4
(COMMAND-4).
Hézode C, Alric L, Brown A, Hassanein T, et al
Antivir Ther.
2015 Aug 27.
Abstract
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in
Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b
Without Baseline NS5A Polymorphisms
McPhee
F, Suzuki Y, Toyota J, et
al
Adv
Ther. 2015 Jul 9
Abstract
Assessment of Drug-Drug Interactions Between Daclatasvir
and Methadone or Buprenorphine/Naloxone.
Garimella T, Wang R, Luo WL, et al
Antimicrob Agents Chemother.
2015 Jun 29
Abstract
Low frequency of drug-resistant virus did not affect the
therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients
with chronic HCV genotype 1 infection.
Kinugasa H,
Ikeda F, Takaguchi K, et al
Antivir Ther.
2015 Jun 26
Abstract
Efficacy of Sofosbuvir and Daclatasvir in Patients with
Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Leroy V, Dumortier J, Coilly A, et al
Clin Gastroenterol Hepatol.
2015 Jun 1
Abstract
Review article: the efficacy and safety of daclatasvir in
the treatment of chronic hepatitis C virus infection
Bunchorntavakul C, Reddy KR.
Aliment Pharmacol Ther.
2015 May 27
Abstract
Daclatasvir, Simeprevir and Ribavirin as a Promising
Interferon-Free Triple Regimen for HCV Recurrence after Liver
Transplant.
Herzer K, Papadopoulos-Köhn A, Walker A, et al
Digestion.
2015 May 19;91(4):326-333.
Abstract
High cure rate with 24 weeks of daclatasvir-based
quadruple therapy in treatment-experienced null-responder HIV/HCV
genotype 1/4 co-infected patients: the ANRS HC 30 QUADRIH study.
Piroth L,
Paniez H, Taburet AM, et al
Clin Infect Dis.
2015 May 14.
Abstract
Daclatasvir in combination with asunaprevir and
beclabuvir for hepatitis C virus genotype 1 infection with compensated
cirrhosis.
Muir AJ, Poordad F, Lalezari J, et al
JAMA.
2015 May 5;313(17):1736-44
Abstract
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
Poordad F, Sievert W, Mollison L, et al;
JAMA. 2015 May 5;313(17):1728-35.
Abstract
Single-dose pharmacokinetics and safety of daclatasvir in
subjects with renal function impairment.
Garimella T, Wang R, Luo WL, et
al
Antivir Ther. 2015 Feb 5.
Abstract
FULL-TEXT ARTICLE
A Randomized Trial of Daclatasvir in Combination With Asunaprevir and
Beclabuvir in Patients With Chronic Hepatitis C Virus Genotype 4
Infection.
Hassanein T, Sims KD, Bennett M, et al
J Hepatol.
2015 Jan 2. pii: S0168-8278(14)00954-4.
Paper
Daclatasvir inhibits hepatitis C virus NS5A motility and
hyper-accumulation of phosphoinositides.
Chukkapalli V, Berger KL, Kelly SM, et al
Virology.
2014 Dec 26;476C:168-179.
Abstract
In Vitro Activity and Resistance Profile of Dasabuvir, a
Non-nucleoside HCV Polymerase Inhibitor.
Kati W, Koev G, Irvin M,
et al
Antimicrob Agents Chemother. 2014 Dec
22.
Abstract
In Vitro Assessment of Re-treatment Options for Patients with Hepatitis
C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir.
Friborg J, Zhou N, Han Z,
Infect Dis Ther.
2014 Dec 17
Abstract
|
Asymmetric Binding to NS5A by Daclatasvir (BMS-790052)
and Analogs Suggests Two Novel Modes of HCV Inhibition.
Nettles JH,
Stanton RA, Broyde J, et al
J Med Chem. 2014
Nov 3
Abstract
Drug-Induced immunoallergic hepatitis during combination therapy with
daclatasvir and asunaprevir.
Fujii Y, Uchida Y, Mochida S.
Hepatology.
2014 Oct 12.
Abstract
Daclatasvir plus Peginterferon and Ribavirin is
Non-inferior to Peginterferon and Ribavirin Alone, and Reduces Duration
of Treatment for HCV Genotype 2 or 3 Infection.
Dore GJ, Lawitz
E, Hézode C, et al
Gastroenterology. 2014 Oct 10
Abstract
Daclatasvir: a team player rather than a prima donna in the treatment of
hepatitis C.
Aghemo A, De Francesco R.
Gut. 2014 Sep 5.
Abstract
Daclatasvir + Asunaprevir: First Global Approval.
Poole RM.
Drugs.
2014 Aug 13
Abstract
The Pharmacokinetics of Daclatasvir and Asunaprevir
Administered in Combination in Studies in Healthy Subjects and Patients
Infected with Hepatitis C Virus.
Eley T, Sevinsky H, Huang SP, et al
Clin
Drug Investig. 2014 Aug 13.
Abstract
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a
multinational, phase 3, multicohort study.
Manns M, Pol S, Jacobson IM, et al
Lancet.
2014 Jul 26.
Abstract
Daclatasvir plus peginterferon alfa and ribavirin for
treatment-naive chronic hepatitis C genotype 1 or 4 infection: a
randomised study.
Hézode C, Hirschfield GM, Ghesquiere
Wm et al
Gut.
2014 Jul 30. pii: gutjnl-2014-307498.
Abstract
Efficacy of daclatasvir in hepatitis C virus.
Izumi N.
Expert Rev Anti Infect Ther.
2014 Jul 25:1-7.
Abstract
Daclatasvir for the treatment of hepatitis C virus infection
Adler H, Lambert JS.
Expert Rev Gastroenterol Hepatol.
2014 May 31:1-14
Abstract
HCV Therapy With Daclatasvir, PEG-IFN, and RBV After Boceprevir-Based
Therapy Failure Post-Liver Transplantation in Hyper-IgM Syndrome.
Reddy KR, Wirjosemito A, Pavri TM, Sinese
L.
Transplantation.
2014 Apr 27;97(8):e47-8
Abstract
Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication
Complex Inhibitor with Potent Clinical Effect."
Belema M, Meanwell NA.
J Med Chem.
2014 Apr 21
Abstract
FULL-TEXT ARTICLE
Daclatasvir plus
sofosbuvir for HCV infection.
Sulkowski MS, Jacobson IM, Nelson DR.
N Engl J Med.
2014 Apr 17;370(16):1560-`1.
Paper
Daclatasvir plus asunaprevir for chronic HCV genotype 1b
infection.
Kumada H, Suzuki Y, Ikeda K
et al
Hepatology. 2014 Mar 6.
Abstract
Efficacy of an Interferon- and Ribavirin-Free Regimen of
Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV
Genotype 1 Infection.
Everson GT, Sims KD, Rodriguez-Torres M, et al
Gastroenterology. 2014 Feb;146(2):420-9.
Abstract
Ultra deep sequencing study of HCV genotype 1 in chronic hepatitis patients
treated with daclatasvir, peg-interferon and ribavirin.
Murakami E, Imamura M, Hayes CN, et al
Antimicrob Agents Chemother.
2014 Jan 27
Abstract
Virologic escape in HCV genotype 1-infected patients receiving daclatasvir
plus ribavirin and peginterferon alfa-2a or alfa-2b.
McPhee F, Hernandez D, Zhou N, et al
Antivir Ther. 2014 Jan 22.
Abstract
A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin
for HCV genotype 1 infection.
Suzuki
F, Toyota J, Ikeda K, et al
Antivir
Ther. 2014 Jan 22.
Abstract
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV
infection.
Sulkowski
MS, Gardiner DF, Rodriguez-Torres M, et al
N Engl J Med. 2014 Jan
16;370(3):211
Abstract
Daclatasvir: The First of a New Class of Drugs Targeted Against
Hepatitis C Virus NS5A.
Gentile
I, Borgia F, Coppola N,
et al
Curr Med Chem.
2013 Dec 28.
Abstract
Effect of the coadministration of daclatasvir on the pharmacokinetics of
a combined oral contraceptive containing ethinyl estradiol and
norgestimate
Bifano M, Sevinsky H, Hwang C, et al
Antivir Ther. 2013
Dec 17
Abstract
Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir,
Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV
Genotype 1 Infection.
Everson GT, Sims KD, Rodriguez-Torres M, et al
Gastroenterology.
2013 Oct 30.
Abstract
Modelling clinical data shows active tissue concentration of
daclatasvir is 10-fold lower than its plasma concentration.
Ke R, Loverdo C, Qi H, et al
J Antimicrob Chemother.
2013 Oct 29
Abstract
A 96-well based analysis of replicon elimination with the HCV NS5A
replication complex inhibitor daclatasvir.
O'Boyle DR 2nd, Nower PT, Sun JH,
et al
J Virol Methods. 2013
Oct;193(1):68-76
Abstract
FULL-TEXT ARTICLE
Daclatasvir: potential role in hepatitis C.
Lee C.
Drug Des Devel Ther.
2013 Oct 16;7:1223-33
Paper
Assessment of pharmacokinetic interactions of the HCV NS5A
replication complex inhibitor daclatasvir with antiretroviral
agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Bifano M, Hwang C, Oosterhuis B,
Antivir Ther.
2013 Aug 20
Abstract
Selection of resistant-associated variants to the NS5A inhibitor
daclatasvir: revenge of the hepatitis C virus
Aghemo A, Colombo M.
Gastroenterology. 2013
Jul;145(1):247-9
Abstract
The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of
action and leads to a new virus half-life estimate.
Guedj J, Dahari H, Uprichard SL, Perelson AS.
Expert Rev Gastroenterol Hepatol.
2013 Jul;7(5):397-9
Abstract
Sofosbuvir and daclatasvir combination therapy in a liver transplant
recipient with severe recurrent cholestatic hepatitis C.
Fontana RJ, Hughes EA, Bifano M, et al
Am J Transplant.
2013 Jun;13(6):1601-5.
Abstract
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV
genotype 1b infection and limited treatment options.
Suzuki Y, Ikeda K, Suzuki F, et al
J Hepatol.
2013 Apr;58(4):655-62.
Abstract
Resistance analysis of hepatitis C virus genotype 1 prior treatment null
responders receiving daclatasvir and asunaprevir.
McPhee F, Hernandez D, Yu F, et al
Hepatology. 2013 Mar
15.
Abstract
FULL-TEXT ARTICLE
Modeling shows
that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter
estimate of the hepatitis C virus half-life.
Guedj J, Dahari H, Rong L, et al
Proc Natl Acad Sci U S A.
2013 Mar 5;110(10):3991-6.
Paper |
Videos
|
A New Way to HIV Functional Cure: HIV Pathogenesis
Sabotage with Dolutegravir |
|
Journal Papers, Abstracts, and Commentaries
|
| |
Dasabuvir (Exviera). Only assessed as part of a
difficult-to-manage combination in hepatitis C.
[No authors listed]
Prescrire Int.
2016 May;25(171):117-20.
Abstract
Dasabuvir : a new direct antiviral agent for
the treatment of hepatitis C.
Trivella JP, Gutierrez J, Martin P.
Expert Opin Pharmacother.
2015 Mar;16(4):617-24.
Abstract
In Vitro Activity and Resistance Profile of
Dasabuvir, a Non-nucleoside HCV Polymerase Inhibitor.
Kati W, Koev G, Irvin M, et al
Antimicrob Agents Chemother.
2014 Dec 22. pii: AAC.04619-14.
Abstract
Dasabuvir: A Non-Nucleoside Inhibitor of NS5B
for the Treatment of Hepatitis C Virus Infection.
Gentile I, Buonomo AR, Borgia G.
Rev Recent Clin Trials.
2014 May 29.
Abstract
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin
for HCV.
Ferenci P, Bernstein D, Lalezari J, et al
N Engl J Med.
2014 May 22;370(21):1983-92.
Abstract
|
Journal
Papers, Abstracts, and Commentaries
Journal
Papers, Abstracts, and Commentaries
| |
|
Real-world use of elbasvir-grazoprevir in patients with chronic
hepatitis C: retrospective analyses from the TRIO network.
Flamm SL, Bacon B, Curry MP,
et al
Aliment Pharmacol Ther. 2018
Apr 17
Abstract
Clinical Pharmacokinetics and Drug-Drug Interactions of
Elbasvir/Grazoprevir.
Kiang TKL.
Eur J Drug Metab Pharmacokinet.
2018 Mar 20.
Abstract
FULL-TEXT ARTICLE
Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating
hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease
patients in France.
Maunoury F, Clément A, Nwankwo C
PLoS One. 2018
Mar 15;13(3):e0194329.
Paper
Efficacy of Elbasvir and Grazoprevir in Participants with Hepatitis C Virus
Genotype 4 Infection: A Pooled Analysis.
Asselah T, Reesink H, Gerstoft J, et al
Liver Int. 2018 Feb 20.
Abstract
Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant
Drugs in Healthy Volunteers.
Feng HP, Caro L, Fandozzi CM,
J Clin Pharmacol. 2018
Jan 12
Abstract
Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic
Hepatitis C Genotype 1 Infection.
Corman S, Elbasha EH, Michalopoulos SN, Nwankwo C.
Value
Health. 2017 Sep;20(8):1110-1120.
Abstract
No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors
Elbasvir/Grazoprevir and Famotidine or Pantoprazole.
Feng HP, Vaddady P, Guo Z,
et al
Clin
Transl Sci. 2017 Jun 17.
Abstract
Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4.
Al-Salama ZT, Deeks ED.
Drugs.
2017 Apr 17.
Abstract
Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on
Hemodialysis.
Martin MT, Koppe S.
Transplantation.
2017 Apr 3.
Abstract
Safety and Efficacy of Elbasvir/Grazoprevir in Patients with
Hepatitis C Virus Infection and Compensated Cirrhosis: an Integrated
Analysis.
Jacobson IM, Lawitz E, Kwo PY, et al
Gastroenterology. 2017 Feb 10.
Abstract
Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus
Infection: A Comprehensive Efficacy and Safety Analysis.
Yao
Y, Yue M, Wang J,
Can
J Gastroenterol Hepatol.
2017;2017:8186275
Abstract
US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with
Chronic Hepatitis C Virus Genotype 1 or 4 Infection.
Boyd SD, Tracy L, Komatsu TE, et al
Clin Drug Investig.
2017 Jan 19.
Abstract
The combination of elbasvir and grazoprevir for the treatment
of chronic HCV infection in Japanese patients: a randomized phase II/III
study.
Kumada H, Suzuki Y, Karino Y,
et al
J
Gastroenterol. 2016 Nov 2
Abstract
Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for
Hepatitis C: A Randomized Trial.
Lawitz E, Poordad F, Gutierrez JA, et al
Hepatology.
2016 Oct 22
Abstract
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without
Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C
Infection.
Kwo P, Gane E, Peng CY, et al
Gastroenterology.
2016 Oct 5
Abstract
FULL-TEXT ARTICLE
C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the
treatment of hepatitis C genotype 1 mono and HIV co-infected patients.
Sarpel D, Dieterich DT.
Ann Transl Med.
2016 Oct;4(Suppl 1):S12.
Paper
Elbasvir and grazoprevir for Chronic Hepatitis C Genotypes 1
and 4.
El Kassas M, Elbaz T, Abd El Latif Y, Esmat G.
Expert Rev Clin Pharmacol.
2016 Sep 7.
Abstract
Elbasvir-Grazoprevir to Treat Hepatitis C Virus
Infection in Persons Receiving Opioid Agonist Therapy: A Randomized
Trial.
Dore GJ, Altice F, Litwin AH, et al
Ann Intern Med.
2016 Aug 9
Abstract
FULL-TEXT ARTICLE
Spotlight on grazoprevir-elbasvir once-daily combination and
its potential in the treatment of hepatitis C.
Suraweera D, Weeratunga AN,
Saab S
Drug Des Devel Ther.
2016 Jun 29;
Paper |
|
|
|
Journal Papers, Abstracts, and Commentaries
|
| |
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney
Transplant Patients With Hepatitis C Virus Infection.
Reau N, Kwo PY,
Rhee S.,et al
Hepatology.
2018 Apr 19.
Abstract
FULL-TEXT ARTICLE
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with
Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2
Study.
Rockstroh JK, Lacombe K, Viani RM, et al
Clin Infect Dis. 2018
Mar 16
Paper
Glecaprevir + pibrentasvir for treatment of hepatitis C.
Carrion AF, Martin P.
Expert Opin Pharmacother.
2018 Feb 21
Abstract
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1
or 3 Infection.
Zeuzem S, Foster GR, Wang S,
et al
N Engl J Med.
2018 Jan 25;378(4):354-369.
Abstract
Effects
of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of
the Glecaprevir and Pibrentasvir Combination in HCV-Negative Subjects.
Kosloski MP, Zhao W, Marbury TC,
et al
Antimicrob Agents Chemother.
2017 Dec 20.
Abstract
Glecaprevir/Pibrentasvir in Patients with HCV Genotype
1 or 4 and Prior Direct-acting Antiviral Treatment Failure.
Poordad F, Pol S, Asatryan A, et al
Hepatology. 2017 Nov
20.
Abstract
Glecaprevir/Pibrentasvir: First Global Approval.
Lamb YN.
Drugs. 2017 Sep 19.
Abstract
Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients
with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized
Phase III Clinical Trial.
Wyles D, Poordad F, Wang S,
Hepatology. 2017 Sep 19
Abstract
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2,
4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a
single-arm, open-label, multicentre phase 3 trial.
Forns X,
Lee SS, Valdes J, et al
Lancet
Infect Dis. 2017 Aug
14.
Abstract
Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and
Pibrentasvir in Healthy Volunteers.
Lin CW, Dutta S, Zhao W, et al
Eur J Drug Metab Pharmacokinet 2017 Jul 7
Abstract |
|
Journal Papers, Abstracts, and Commentaries
|
|
General
Reports
HCV
Protease Inhibitors